Dec. 2 Quick Takes: $109M series C for Acepodia
Plus Tune catches $40M series A from NEA, Emerson, and Astellas-Dyno, Omeros, Vir and more
A $109 million series C round will enable Acepodia Inc. to advance its antibody-cell conjugation (ACC) platform and cell therapies for cancer. Acepodia has global rights to components of the ACC technology from Carolyn Bertozzi’s lab at the University of California Berkeley, where co-founder, President and CEO Sonny Hsiao was a graduate student. The Alameda, Calif., biotech has raised $166 million to date in venture money. Digital Mobile Venture led the financing, with the firm’s Samuel Chen joining Acepodia’s board.
Tune Therapeutics Inc. launched Thursday with $40 million in funding co-led by New Enterprise Associates and Emerson Collective. The company is deploying its TEMPO platform to modify epigenomic cell machinery to control gene expression in undisclosed indications. Hatteras Venture Partners, Mission BioCapital, Saisei Ventures and Alexandria Venture Investments joined the round...